Critical Limb Ischemia-Pipeline Review, H1 2017

Critical Limb Ischemia-Pipeline Review, H1 2017


  • Products Id :- GMDHC9300IDB
  • |
  • Pages: 126
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Critical Limb Ischemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia-Pipeline Review, H1 2017, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 12, 4 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Critical Limb Ischemia-Overview

Critical Limb Ischemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Critical Limb Ischemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Critical Limb Ischemia-Companies Involved in Therapeutics Development

AnGes MG Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Ltd

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kasiak Research Pvt Ltd

Kowa Company Ltd

Neurofx Inc

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Symic Biomedical Inc

TikoMed AB

U.S. Stem Cell Inc

Vericel Corp

VESSL Therapeutics Ltd

ViroMed Co Ltd

Critical Limb Ischemia-Drug Profiles

ACP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AdipoCell-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alecmestencel-T-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASCT-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beperminogene perplasmid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Activate FGF2 for Critical Limb Ischemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-CLI-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLBS-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DVC-10101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Critical Limb Ischemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-016-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixmyelocel-T-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MultiGeneAngio-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFx-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-104 NP-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05285401-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-PAD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Refacell-CLI-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rejuveinix-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReN-009-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-030-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovacular Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Critical Limb Ischemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Critical Limb Ischemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-700-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-302-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Critical Limb Ischemia-Dormant Projects

Critical Limb Ischemia-Discontinued Products

Critical Limb Ischemia-Product Development Milestones

Featured News & Press Releases

Jan 17, 2017: Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

Jan 10, 2017: Pluristem's Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA

Nov 01, 2016: Pluristem's Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency

Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada

Sep 08, 2016: Pluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular Medicine

Aug 09, 2016: Pluristem's Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe's Horizon 2020 Program

Aug 02, 2016: Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

Jul 27, 2016: Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture

Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia

Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles

Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia

Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study

Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States

Dec 21, 2015: Pluristem Reaches Agreement with Japan's PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated Pathway

Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Critical Limb Ischemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Critical Limb Ischemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Critical Limb Ischemia-Pipeline by AnGes MG Inc, H1 2017

Critical Limb Ischemia-Pipeline by apceth Biopharma GmbH, H1 2017

Critical Limb Ischemia-Pipeline by Athersys Inc, H1 2017

Critical Limb Ischemia-Pipeline by BiogenCell Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Caladrius Biosciences Inc, H1 2017

Critical Limb Ischemia-Pipeline by Cynata Therapeutics Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Hemostemix Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Histocell SL, H1 2017

Critical Limb Ischemia-Pipeline by ID Pharma Co Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Integene International Holdings LLC, H1 2017

Critical Limb Ischemia-Pipeline by Juventas Therapeutics Inc, H1 2017

Critical Limb Ischemia-Pipeline by Kasiak Research Pvt Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Kowa Company Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Neurofx Inc, H1 2017

Critical Limb Ischemia-Pipeline by Pharmicell Co Ltd, H1 2017

Critical Limb Ischemia-Pipeline by Pluristem Therapeutics Inc, H1 2017

Critical Limb Ischemia-Pipeline by ReNeuron Group Plc, H1 2017

Critical Limb Ischemia-Pipeline by Symic Biomedical Inc, H1 2017

Critical Limb Ischemia-Pipeline by TikoMed AB, H1 2017

Critical Limb Ischemia-Pipeline by U.S. Stem Cell Inc, H1 2017

Critical Limb Ischemia-Pipeline by Vericel Corp, H1 2017

Critical Limb Ischemia-Pipeline by VESSL Therapeutics Ltd, H1 2017

Critical Limb Ischemia-Pipeline by ViroMed Co Ltd, H1 2017

Critical Limb Ischemia-Dormant Projects, H1 2017

Critical Limb Ischemia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Critical Limb Ischemia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AnGes MG Inc, apceth Biopharma GmbH, Athersys Inc, BiogenCell Ltd, Caladrius Biosciences Inc, Cynata Therapeutics Ltd, Hemostemix Ltd, Histocell SL, ID Pharma Co Ltd, Integene International Holdings LLC, Juventas Therapeutics Inc, Kasiak Research Pvt Ltd, Kowa Company Ltd, Neurofx Inc, Pharmicell Co Ltd, Pluristem Therapeutics Inc, ReNeuron Group Plc, Symic Biomedical Inc, TikoMed AB, U.S. Stem Cell Inc, Vericel Corp, VESSL Therapeutics Ltd, ViroMed Co Ltd

Critical Limb Ischemia Therapeutic Products under Development, Key Players in Critical Limb Ischemia Therapeutics, Critical Limb Ischemia Pipeline Overview, Critical Limb Ischemia Pipeline, Critical Limb Ischemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 142760
Site License
USD 4000 INR 285520
Corporate User License
USD 6000 INR 428280

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com